IL-PRICEFX
14.5.2020 15:32:04 CEST | Business Wire | Press release
Pricefx , the global leader in native cloud pricing software, today introduced Lightning , the first turnkey solution to enable rapid activation of pricing excellence. Powered by Pricefx Accelerators, Lightning delivers a full suite of standard pricing analytics, management and CPQ realization tools, able to go live in six weeks or less. Customers can accelerate their Pricefx implementation with fast, easy to deploy, pre-configured pricing capabilities.
Businesses are increasingly considering pricing software as a way to navigate the current economic climate. Yet when trying to improve their enterprise pricing approach, customers can face a steep climb to reach activation.
“In my experience, it’s not uncommon for companies to struggle getting started with pricing software,” said Robert Kugel, Senior Vice President and Research Director at Ventana Research. “Starting with a blank whiteboard and getting all stakeholders to agree on the strategy, rules, fundamental approaches and a budget can derail a project before it gets off the ground. With Lightning, Pricefx is attempting to address these challenges by offering pre-configured pricing capabilities out of the box. Using a point-click-deploy approach, Pricefx Lightning is designed to significantly reduce the barriers to adopting a full scope pricing solution.”
Pricefx Lightning offers industry standard, pre-configured foundations for analytics dashboards, pre-defined yet flexible pricing strategies, and instant communication to the field. Removing the friction from implementing a full scope pricing solution, Pricefx offers a point-click-deploy approach designed to empower users who only need to add data to get started. This allows organizations to start the process from the halfway point, skipping weeks or months working through initial configurations.
Once up and running, Pricefx enables users to refine and customize focused on their specific business needs, removing costly proof of concept cycles spent on defining basic requirements. Powered by Pricefx PriceAnalyzer and Sales Insights Accelerator, Lightning provides a powerful pre-configured data analytics environment of out-of-the-box dashboards with more than a dozen optional additional configurations. To gain pricing insights, users simply load their data and start seeing new opportunities for growth and improvement.
To activate analytics-powered insights, Pricefx Lightning provides a robust price setting and management capability connected directly into the customer’s analytics, making the implementation of new intelligence seamless and instant. The analytics and management are natively integrated into the platform, which allows the strategy to be delivered to the field organization in real time. Pricefx pricing platform uses a full featured CPQ including standard workflows, in-line approvals, chat and e-signature support, removing any barriers to delivering pricing excellence.
“Lightning is a first-of-its-kind, tech-enabled fast lane for pricing excellence, designed to supercharge your implementation without breaking the bank,” said Marcin Cichon, CEO and co-founder at Pricefx. “At the outset of this initiative, our goal was to skip the POC stage and get customers working with a live product. We believe that by delivering out-of-the-gate value Pricefx can provide an informed launch point that enables businesses to focus on enhancements that create a competitive advantage and build organizational alignment with real data and results. With Lightning, we can dramatically accelerate time-to-value and have customers running live in six weeks – no one else on the market can deliver that.”
Lightning is the result of 18 months of work, with dozens of customers in more than 10 vertical industries. Its broad, versatile and flexible standard set of pre-configurations are designed to meet the analytics, management and realization needs of any organization looking to rapidly improve their entire pricing capability.
Lightning is free to activate through June 2020 with a signed subscription agreement for the three modules that power the solution – PriceAnalyzer , PriceBuilder and QuoteConfigurator . Interested customers should contact their current Pricefx representative for more information .
About Pricefx
Established in 2011 in Germany, Pricefx is the global leader in SaaS pricing software, offering a comprehensive suite of solutions that are fast to implement, flexible to configure and customize, and friendly to learn and use. Pricefx delivers a complete price optimization and management platform based on native cloud architecture, providing industry leading time to value and total cost of ownership advantages to customers. Their innovative solution works for both B2B and B2C enterprises of any size, in any industry, in any part of the world. Pricefx’s business model is entirely based on the satisfaction and loyalty of its customers. Today, Pricefx delivers Passion for Pricing to more than 100 customers in more than 37 countries worldwide. For more information, please visit www.pricefx.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200514005236/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom